黑色素瘤中酪氨酸激酶抑制剂的耐药模式：新的认识。
Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights.
机构信息
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
出版信息
Curr Opin Oncol. 2012 Mar;24(2):150-4. doi: 10.1097/CCO.0b013e32834fca92.
PURPOSE OF REVIEW
After years of therapeutic approaches with limited effects in metastatic melanoma, new inhibitors of serine-threonine and tyrosine kinases have demonstrated impressive clinical efficacy and improved survival.
RECENT FINDINGS
This review explains the molecular background for the development of specific kinase inhibitors and briefly summarizes their clinical impact on advanced melanoma.
SUMMARY
Despite robust early clinical efficacy, the antiproliferative effect of these kinase inhibitors is limited. The resistance mechanisms are explored currently and will help to identify new targets for melanoma therapy.
目的综述
在转移性黑色素瘤的治疗方法多年收效有限之后，丝氨酸-苏氨酸和酪氨酸激酶的新型抑制剂显示出了令人瞩目的临床疗效和生存改善。
最近的发现
本文解释了特定激酶抑制剂开发的分子背景，并简要总结了它们对晚期黑色素瘤的临床影响。
总结
尽管这些激酶抑制剂具有强大的早期临床疗效，但它们的抗增殖作用有限。目前正在探索耐药机制，这将有助于确定黑色素瘤治疗的新靶点。
Zotero 插件